Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0NSYHL
ADC Name
Promiximab-MMAE
Synonyms
Promiximab MMAE
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Small cell lung cancer [ICD11:2C25]
Investigative
Drug-to-Antibody Ratio
3.13
Antibody Name
Promiximab
  Antibody Info 
Antigen Name
Neural cell adhesion molecule 1 (NCAM1)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
Vedotin
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 6 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 78.9
%
NCI-H69 cells
Small cell lung carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 89.5
%
NCI-H69 cells
Small cell lung carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 90
%
NCI-H526 cells
Lung small cell carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 91
%
NCI-H526 cells
Lung small cell carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
NCI-H69 cells
Small cell lung carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
NCI-H526 cells
Lung small cell carcinoma
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.32
nM
NCI-H69 cells
Small cell lung carcinoma
Half Maximal Inhibitory Concentration (IC50) 
5.23
nM
NCI-H526 cells
Lung small cell carcinoma
Half Maximal Inhibitory Concentration (IC50) 
19.24
nM
NCI-H524 cells
Lung small cell carcinoma
Half Maximal Inhibitory Concentration (IC50) 
> 1200
nM
NK cells
Normal
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 78.90% (Day 37) Positive CD56 expression (CD56 +++/++)
Method Description
One or two weeks later until the tumor sizes reached about 200 mm3, the mice were divided into four groups, with 6-7 mice in each group. Promiximab-MMAE (2.5 mg/kg), Promiximab (10 mg/kg) and a control (vehicle) were administered via tail vein into the mice every three days, with a total of three times.
In Vivo Model NCI-H69 CDX model
In Vitro Model Small cell lung carcinoma NCI-H69 cells CVCL_1579
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 89.50% (Day 37) Positive CD56 expression (CD56 +++/++)
Method Description
One or two weeks later until the tumor sizes reached about 200 mm3, the mice were divided into four groups, with 6-7 mice in each group. Promiximab-MMAE (5 mg/kg), Promiximab (10 mg/kg) and a control (vehicle) were administered via tail vein into the mice every three days, with a total of three times.
In Vivo Model NCI-H69 CDX model
In Vitro Model Small cell lung carcinoma NCI-H69 cells CVCL_1579
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 90.00% (Day 37) Positive CD56 expression (CD56 +++/++)
Method Description
One or two weeks later until the tumor sizes reached about 200 mm3, the mice were divided into four groups, with 6-7 mice in each group. Promiximab-MMAE (10 mg/kg), Promiximab (10 mg/kg) and a control (vehicle) were administered via tail vein into the mice every three days, with a total of three times.
In Vivo Model NCI-H526 CDX model
In Vitro Model Lung small cell carcinoma NCI-H526 cells CVCL_1569
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 91.00% (Day 37) Positive CD56 expression (CD56 +++/++)
Method Description
One or two weeks later until the tumor sizes reached about 200 mm3, the mice were divided into four groups, with 6-7 mice in each group. Promiximab-MMAE (10 mg/kg), Promiximab (10 mg/kg) and a control (vehicle) were administered via tail vein into the mice every three days, with a total of three times.
In Vivo Model NCI-H526 CDX model
In Vitro Model Lung small cell carcinoma NCI-H526 cells CVCL_1569
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 37) Positive CD56 expression (CD56 +++/++)
Method Description
One or two weeks later until the tumor sizes reached about 200 mm3, the mice were divided into four groups, with 6-7 mice in each group. Promiximab-MMAE (10 mg/kg), Promiximab (10 mg/kg) and a control (vehicle) were administered via tail vein into the mice every three days, with a total of three times.
In Vivo Model NCI-H69 CDX model
In Vitro Model Small cell lung carcinoma NCI-H69 cells CVCL_1579
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 37) Positive CD56 expression (CD56 +++/++)
Method Description
One or two weeks later until the tumor sizes reached about 200 mm3, the mice were divided into four groups, with 6-7 mice in each group. Promiximab-MMAE (10 mg/kg), Promiximab (10 mg/kg) and a control (vehicle) were administered via tail vein into the mice every three days, with a total of three times.
In Vivo Model NCI-H526 CDX model
In Vitro Model Lung small cell carcinoma NCI-H526 cells CVCL_1569
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.32 nM Positive CD56 expression (CD56 +++/++)
Method Description
SCLC cell lines and human NK cells were treated with various concentrations of Promiximab and Promiximab-MMAE for 72 h.
In Vitro Model Small cell lung carcinoma NCI-H69 cells CVCL_1579
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 5.23 nM Positive CD56 expression (CD56 +++/++)
Method Description
SCLC cell lines and human NK cells were treated with various concentrations of Promiximab and Promiximab-MMAE for 72 h.
In Vitro Model Lung small cell carcinoma NCI-H526 cells CVCL_1569
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 19.24 nM Positive CD56 expression (CD56 +++/++)
Method Description
SCLC cell lines and human NK cells were treated with various concentrations of Promiximab and Promiximab-MMAE for 72 h.
In Vitro Model Lung small cell carcinoma NCI-H524 cells CVCL_1568
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 1200 nM Negative CD56 expression (CD56 -)
Method Description
SCLC cell lines and human NK cells were treated with various concentrations of Promiximab and Promiximab-MMAE for 72 h.
In Vitro Model Normal NK cells Homo sapiens
References
Ref 1 Preparation and anti-cancer evaluation of promiximab-MMAE, an anti-CD56 antibody drug conjugate, in small cell lung cancer cell line xenograft models. J Drug Target. 2018 Dec;26(10):905-912. doi: 10.1080/1061186X.2018.1450413. Epub 2018 Apr 13.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.